Radiolabelling of glycosylated MFE-23::CPG2 fusion protein (MFECP1) with 99mTc for quantitation of tumour antibody-enzyme localisation in antibody-directed enzyme pro-drug therapy (ADEPT).

MLA

Francis, R. J., et al. “Radiolabelling of Glycosylated MFE-23::CPG2 Fusion Protein (MFECP1) with 99mTc for Quantitation of Tumour Antibody-Enzyme Localisation in Antibody-Directed Enzyme pro-Drug Therapy (ADEPT).” European Journal of Nuclear Medicine & Molecular Imaging, vol. 31, no. 8, Aug. 2004, pp. 1090–96. EBSCOhost, https://doi.org/10.1007/s00259-004-1474-4.

APA

Francis, R. J., Mather, S. J., Chester, K., Sharma, S. K., Bhatia, J., Pedley, R. B., Waibel, R., Green, A. J., & Begent, R. H. J. (2004). Radiolabelling of glycosylated MFE-23::CPG2 fusion protein (MFECP1) with 99mTc for quantitation of tumour antibody-enzyme localisation in antibody-directed enzyme pro-drug therapy (ADEPT). European Journal of Nuclear Medicine & Molecular Imaging, 31(8), 1090–1096. https://doi.org/10.1007/s00259-004-1474-4

Chicago

Francis, R. J., S. J. Mather, K. Chester, S. K. Sharma, J. Bhatia, R. B. Pedley, R. Waibel, A. J. Green, and R. H. J. Begent. 2004. “Radiolabelling of Glycosylated MFE-23::CPG2 Fusion Protein (MFECP1) with 99mTc for Quantitation of Tumour Antibody-Enzyme Localisation in Antibody-Directed Enzyme pro-Drug Therapy (ADEPT).” European Journal of Nuclear Medicine & Molecular Imaging 31 (8): 1090–96. doi:10.1007/s00259-004-1474-4.